A challenge to independent information: The Information to Patients’ Directive

Teresa Leonardo Alves

November 2009
Poland
This presentation arises from the Developing Rational Use of Medicines in Europe project, which has received funding from the European Union, in the framework of the Health programme.
What is HAI Europe?

• European branch of a not-for-profit global network
• Established in 1981
• Made up by consumers, public interest NGOs, health care providers, academics, media and individuals
• Europe office: Amsterdam, The Netherlands
• Works to promote access to essential medicines and their rational use
What this presentation covers...

- Policy discussions in Europe: History of Events and Actors at play
- What are the changes proposed in the Information to Patients directive?
- Unbranded ‘disease awareness’ campaigns in Europe
- A word of caution
<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bravo</td>
<td>0.30%</td>
</tr>
<tr>
<td>Real advance</td>
<td>2.34%</td>
</tr>
<tr>
<td>Offers some benefit</td>
<td>6.81%</td>
</tr>
<tr>
<td>Can help</td>
<td>14.60%</td>
</tr>
<tr>
<td>Nothing new</td>
<td>69.02%</td>
</tr>
<tr>
<td>Innaceptable</td>
<td>3.18%</td>
</tr>
<tr>
<td>No decision</td>
<td>3.83%</td>
</tr>
</tbody>
</table>

La Revue Prescrire, 2006
In 1900...
Drug Promotion – a conflict?

Public Interest

- Rational use of medicines

Pharmaceutical Industry Interest

- Maximize sales and returns to shareholders
2001 - Proposal for change of EU advertising laws

- EU Commission proposed a pilot project to allow direct-to-consumer advertising in Europe for asthma, diabetes and AIDS drugs

- **What was said:**

  “This is not direct to consumer advertising. We are not introducing advertising for prescription drugs. What we want to do is, as a test case...to make sure that validated and patient oriented information can be made available...”

  — Commissioner Erkki Liikanen, July 2001
Proposed legislative change included:
• “public advertising of 3 classes of products…”
• Amendment to Article 88, which prohibits advertising of prescription drugs to the public;
• No explicit exclusion of any form of advertising, in any media.
The proposal was overwhelmingly rejected

- By the European Parliament in 2002: \textbf{494 to 42}
- And again by the EU Council in 2003.

...5 years down the road...
European Political Landscape

- Pharmaceuticals still governed by DG Enterprise
- New, vocal and heavily industry-supported patient groups came into play
- One more high-level group: Pharmaceutical Forum
- Similar initiative: now disguised as information to patients
Proposed directive on Information to Patients

• Companies would be able to disseminate:
  – The information contained in the SPC and package leaflet, but presented in a different way
  – Prices, information on pack changes and adverse-reaction warnings
  – Information on non-interventional studies

• Authorised channels:
  • Internet
  • In “health-related publications” – To be defined...

• Specifically rejects comparative information
Déjà vu?

Information « » Advertising
What is prohibited under current EU legislation?

EU Directive:

• Article 88 (a) prohibits advertising of prescription drugs to the public
• Article 86 (2) allows information on diseases, as long as there is no direct or indirect reference to a specific product
Pfizer Campaign Portugal, 2007

More than 6 weeks without smoking and no arguments yet.

Stop smoking without dramas, visit your doctor.

What is left unsaid:
Pfizer has a product to sell: varenicline FDA and EMEA warnings on side-effects: depression, suicidal ideation, emotional changes.
Skip your period campaign by Bayer Schering in The Netherlands, 2007

Leaflet distributed at pharmacies

What is left unsaid:

- DTCA: Illegal
- Direct reference to products which have been approved for specific indications
- Positive comments about company’s medicines
- Suggested product is under FDA scrutiny: concerns about side-effects – DVT - company made unsupported claims in advertising

### Table: Uitstellen menstruatie bij pilgebruikers

<table>
<thead>
<tr>
<th>Merk pil</th>
<th>Uitstel</th>
<th>Duur</th>
<th>Opmerking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yasmin</td>
<td>geen stopweek, direct doorgaan met nieuwe strip</td>
<td>zolang als gewenst</td>
<td>geen afname betrouwbaarheid</td>
</tr>
<tr>
<td>Femodeen Minulet</td>
<td>Zie het advies bij Yasmin®</td>
<td>Zie het advies bij Yasmin®</td>
<td></td>
</tr>
<tr>
<td>Microgynon 20/ Lovette</td>
<td>Zie het advies bij Yasmin®</td>
<td>Zie het advies bij Yasmin®</td>
<td></td>
</tr>
<tr>
<td>Microgynon 30/ Stedril 30</td>
<td>Zie het advies bij Yasmin®</td>
<td>Zie het advies bij Yasmin®</td>
<td></td>
</tr>
<tr>
<td>Marvelon</td>
<td>Zie het advies bij Yasmin®</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mercilon</td>
<td>Zie het advies bij Yasmin®</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trigynon/ Trinordiol</td>
<td>geen stopweek, doorgaan met de derde fase uit de nieuwe strip. Dit zijn de 10 gele dragees. Voor langer uitstel doorgaan met Microgynon® 30</td>
<td>geen afname betrouwbaarheid</td>
<td></td>
</tr>
<tr>
<td>Progesteron</td>
<td>Zie het advies bij Yasmin®</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Unbranded pharmaceutical advertising

• “Disease-mongering” – expanded disease definitions in order to increase sales

• Inaccuracies about disease prevalence, risks, potential treatment benefits

• Failure to comply with standards in WHO Ethical Criteria

• Regulatory response is generally inadequate
NOVARTIS TV ads, The Netherlands
*Ethical Criteria definition of promotion: to stimulates sales*

- 't Jong GW et al. *British Medical Journal* 2004;328:931
Problems

• Companies have an inherent conflict of interest
• Public dissemination of promotional information about prescription-only medicines
  – Increase in consumption and costs
  – Increase in irrational use
• Reminder adverts would be allowed: emotive branding images and messages
• Checking information before release will not solve the problem
  – Big burden on public authorities
  – Waste of resources: human and financial
• Self-regulation is not a solution
What is happening…

- Opposition from public-health related groups, consumers, payers, healthcare professionals, independent patient organisations
- EU Council expressed grave concerns
- Commission Directive is now being discussed at EU Parliament
- Essential to mobilize CSO voice: Your voice!
Public health and welfare first!

- The public needs unbiased, accurate, comparative information on the pros and cons of all treatment choices, including the option not to treat – not disguised or undisguised advertising.

- Legislation banning unethical drug promotion should be enacted and enforced.

- Industry has a clear role to play:
  - Improve quality of product information, packaging and patient information leaflets;
  - Full public disclosure of all pre- and post- market drug effectiveness and safety studies.
The information to patients directive...

...is not what it seems!
Group Activities

- Break-up in small groups
- Practical Exercises
  - To critically appraise an advert
  - Each group selects one rapporteur, who then presents to plenary
- Joint Discussion
Group Exercise

- Look at the image, title and text
- Who is the target audience?
- What are the key messages?
- What is mentioned:
  - About the treatment benefits?
  - About the treatment risks?
- What is included?
- What is missing?